BR112017008962A2 - proteínas de fusão inibidoras de c1 esterase e usos das mesmas - Google Patents

proteínas de fusão inibidoras de c1 esterase e usos das mesmas

Info

Publication number
BR112017008962A2
BR112017008962A2 BR112017008962-9A BR112017008962A BR112017008962A2 BR 112017008962 A2 BR112017008962 A2 BR 112017008962A2 BR 112017008962 A BR112017008962 A BR 112017008962A BR 112017008962 A2 BR112017008962 A2 BR 112017008962A2
Authority
BR
Brazil
Prior art keywords
complement
fusion proteins
inh
inhibiting fusion
present
Prior art date
Application number
BR112017008962-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Norton Angela
Pan Clark
Iskenderian Andrea
Strack-Logue Bettina
Original Assignee
Shire Human Genetic Therapies, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies, Inc filed Critical Shire Human Genetic Therapies, Inc
Publication of BR112017008962A2 publication Critical patent/BR112017008962A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
BR112017008962-9A 2014-10-31 2015-10-31 proteínas de fusão inibidoras de c1 esterase e usos das mesmas BR112017008962A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073657P 2014-10-31 2014-10-31
US62/073,657 2014-10-31
PCT/US2015/058521 WO2016070156A2 (en) 2014-10-31 2015-10-31 C1 esterase inhibitor fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
BR112017008962A2 true BR112017008962A2 (pt) 2018-01-16

Family

ID=54548264

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008962-9A BR112017008962A2 (pt) 2014-10-31 2015-10-31 proteínas de fusão inibidoras de c1 esterase e usos das mesmas

Country Status (10)

Country Link
US (1) US20160130324A1 (enExample)
EP (2) EP3212663B1 (enExample)
JP (3) JP6740225B2 (enExample)
KR (2) KR20240035643A (enExample)
CN (2) CN107108753A (enExample)
AU (2) AU2015338913B2 (enExample)
BR (1) BR112017008962A2 (enExample)
CA (1) CA2964132A1 (enExample)
MA (1) MA53991A (enExample)
WO (1) WO2016070156A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087882A1 (en) * 2015-11-19 2017-05-26 Shire Human Genetic Therapies, Inc. Recombinant human c1 esterase inhibitor and uses thereof
EP3504648A1 (en) 2016-08-23 2019-07-03 CSL Behring GmbH Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
AU2018281337B2 (en) 2017-06-06 2022-08-25 Relinia, Inc. Single-chain TNF receptor 2 agonist fusion proteins
SG11202008821PA (en) * 2017-06-20 2020-10-29 Sichuan Baili Pharm Co Ltd Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (tdc)
US20210317168A1 (en) * 2018-10-15 2021-10-14 The Regents Of The University Of California Complement Component 1s (C1s) Deficient Cells for Production of Vaccines and Biopharmaceutical Proteins
JP2022536692A (ja) * 2019-06-11 2022-08-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 調節不全の血漿カリクレインによって媒介される疾患の治療のための抗体のアデノ随伴ウイルスベクター送達
CN111087475B (zh) * 2019-12-25 2022-07-08 东莞市东阳光生物药研发有限公司 Fgf21融合蛋白及抑制其降解的方法
CN113493519B (zh) * 2020-03-19 2022-12-27 浙江道尔生物科技有限公司 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白
WO2022109124A1 (en) 2020-11-20 2022-05-27 Csl Behring Gmbh Method for treating antibody-mediated rejection
WO2025072726A1 (en) 2023-09-29 2025-04-03 Trex Bio, Inc. Tnf-alpha variant fusion molecules

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
FR2672895B1 (fr) 1991-02-15 1995-05-12 Transgene Sa Procede de purification d'une proteine fortement glycosylee.
WO1992022320A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
ATE336514T1 (de) * 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
CA2405550A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
PL376381A1 (en) 2002-07-15 2005-12-27 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
US8524477B2 (en) 2002-10-29 2013-09-03 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
US7384754B2 (en) 2003-10-31 2008-06-10 Agilent Technologies, Inc. Enrichment and tagging of glycosylated proteins
ZA200701484B (en) * 2004-08-03 2008-07-30 Biorexis Pharmaceutical Corp Combination therapy using transferrin fusion proteins comprising GLP-1
GB0507123D0 (en) 2005-04-08 2005-05-11 Isis Innovation Method
EP1896503B1 (en) 2005-05-31 2014-10-29 Board of Regents, The University of Texas System IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF
EP2495308A1 (en) 2005-12-08 2012-09-05 Amgen Inc. Improved production of glycoproteins using manganese
US20070249014A1 (en) 2006-02-10 2007-10-25 Invitrogen Corporation Labeling and detection of post translationally modified proteins
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
IL182956A0 (en) 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
AU2008310583A1 (en) 2007-10-12 2009-04-16 Sigma-Aldrich Co. Llc Compositions and methods for improved glycoprotein sialylation
MY161892A (en) 2008-02-19 2017-05-15 Biocon Ltd A method of obtaining a purified, biologically active heterologous protein
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
CN102317309A (zh) 2009-02-26 2012-01-11 巴特勒能源同盟有限公司 通过不同的翻译后修饰改变和调节蛋白质活性
EP2504360B1 (en) 2009-11-23 2018-08-15 Amgen Inc. Monomeric antibody fc
EP2543730B1 (en) * 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2011116291A1 (en) * 2010-03-18 2011-09-22 Thrombolytic Science International Production of human c1 inhibitor in human cells
US20120010013A1 (en) * 2010-06-19 2012-01-12 Fellows Edwin E Swing assistant device
US20130177555A1 (en) 2010-08-13 2013-07-11 Medimmune Limited Monomeric Polypeptides Comprising Variant FC Regions And Methods Of Use
CN103429261A (zh) * 2010-12-22 2013-12-04 塞法隆澳大利亚股份有限公司 半寿期改进的修饰抗体
ES2563763T3 (es) 2011-02-10 2016-03-16 F. Hoffmann-La Roche Ag Método para la purificación de un glicano y/o un glicoconjugado mediante cromatografía usando un algodón que comprende la fase estacionaria
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
KR20160044598A (ko) * 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
UA124083C2 (uk) * 2011-06-28 2021-07-21 ІНГІБРЕКС, Інк. Злитий серпіновий поліпептид і спосіб його застосування
CN103814044A (zh) 2011-07-08 2014-05-21 默沙东公司 纯化fc-融合蛋白的方法
CN102890790B (zh) * 2011-07-22 2014-04-30 鸿富锦精密工业（深圳）有限公司 扩展卡
WO2013093760A2 (en) 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
EP2793935B1 (en) * 2011-12-22 2016-05-25 CSL Behring GmbH Use of c1-inhibitor for the treatment of secondary edema of the central nervous system
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
WO2013138643A1 (en) 2012-03-16 2013-09-19 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Soluble engineered monomeric fc
EP2928917B1 (en) 2012-12-07 2018-02-28 Pfizer Inc Engineered monomeric antibody fragments
US10286047B2 (en) * 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
EP3431592A1 (en) * 2013-03-14 2019-01-23 Translate Bio, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
DK2796145T3 (da) * 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro

Also Published As

Publication number Publication date
CN113698495B (zh) 2025-06-06
JP6740225B2 (ja) 2020-08-12
AU2021200977A1 (en) 2021-03-11
KR20240035643A (ko) 2024-03-15
CN107108753A (zh) 2017-08-29
CA2964132A1 (en) 2016-05-06
US20160130324A1 (en) 2016-05-12
HK1243443A1 (en) 2018-07-13
WO2016070156A3 (en) 2016-06-23
JP2018503355A (ja) 2018-02-08
EP3769780A1 (en) 2021-01-27
AU2015338913B2 (en) 2020-11-19
AU2015338913A1 (en) 2017-05-04
CN113698495A (zh) 2021-11-26
KR20170074244A (ko) 2017-06-29
KR102753264B1 (ko) 2025-01-10
JP2020202841A (ja) 2020-12-24
EP3212663A2 (en) 2017-09-06
WO2016070156A2 (en) 2016-05-06
EP3212663B1 (en) 2020-05-27
JP2023027290A (ja) 2023-03-01
MA53991A (fr) 2021-09-15

Similar Documents

Publication Publication Date Title
BR112017008962A2 (pt) proteínas de fusão inibidoras de c1 esterase e usos das mesmas
BR112018010160A2 (pt) inibidor da c1 esterase humana recombinante e usos do mesmo
BR112017017286A2 (pt) protease de cisteína
BR112017017284A2 (pt) protease de cisteína
CO2017004489A2 (es) Polipéptidos fgf-21 modificados
BR112017021970A2 (pt) bioconjugados e usos dos mesmos
BR112015013311A2 (pt) indução de tolerancia e reparação de mutação do fator 8
CL2018002826A1 (es) Proteínas f de prefusión del virus respiratorio sincicial (vrs) solubles y estabilizadas
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
EP4275705A3 (en) Pancreatitis treatment
BR112017025728A2 (pt) fragmentos mutantes da proteína ras
BR112017002761A2 (pt) composições anti-metanogênicas e usos das mesmas
EP3674314A3 (en) Apelin polypeptides
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
EP4299129A3 (en) Dosing regimen for treatment of cognitive impairments with blood plasma products
BR112016013138A2 (pt) mistura de peptídeos
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
EA201990257A1 (ru) Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
BR112019003785A2 (pt) tabaco resistente a vírus e método de melhoramento para o mesmo
BR112016015678B1 (pt) Polipeptídeo compreendendo um fragmento de ospa de c-terminal híbrido, seu processo de produção, seu uso, ácido nucleico, vetor, célula hospedeira, composição farmacêutica
BR112018067747A2 (pt) proteínas de fusão recombinantes de folistatina-fc e uso no tratamento da distrofia muscular de duchenne
BR112016011489A2 (pt) composição nutricional pediátrica com peptídeos do leite para crescimento e desenvolvimento saudável
BR112017022653A2 (pt) ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph?
CL2017003144A1 (es) Péptidos lipidados resistentes a proteasas
BR112017008805A2 (pt) tratamento de córnea usando laminina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]